Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 112,611

Document Document Title
WO/2016/027844A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R represents a methyl group or the like; R1 represents a fluorine atom or the like; R2 represents a hydrogen atom or a fluorine atom; R...  
WO/2016/027168A2
A splice modulating oligonucleotide (SMO), is provided having a sequence designed to modulate the splicing of a SCN8A pre-mRNA, wherein the SMO sequence specifically binds to a sequence in the SCN8A pre-mRNA. Certain embodiments of the i...  
WO/2016/027241A1
The invention relates to a compound of formula (I) wherein X1 to X4 and RC to RG are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2016/027168A3
A splice modulating oligonucleotide (SMO), is provided having a sequence designed to modulate the splicing of a SCN8A pre-mRNA, wherein the SMO sequence specifically binds to a sequence in the SCN8A pre-mRNA. Certain embodiments of the i...  
WO/2016/028811A1
A composition for relieving pain, and methods of making and using the composition, whereby the composition comprises an amount of sugar or sugar alcohol; and an amount of vehicle; wherein the composition is formulated for transdermal adm...  
WO/2016/027259A1
The present invention is directed to pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a central nervous system (CNS) active agent and pseudoephedrine (PSE), phenylephrine (PHE), or both. In some em...  
WO/2016/025829A1
Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/...  
WO/2016/025533A3
In some aspects, described herein are methods of treating synucleinopathies using FK506.  
WO/2016/023997A1
The present invention relates to a chemical compound having the general formula (I): wherein R1 and R2 are, equal or independently, aryl, heteroaryl; wherein RTA is a 2-1,3-, or 4- 1,3- or 5-1,3-thiazole ring and its use in for improving...  
WO/2016/025745A9
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form o...  
WO/2016/025721A1
This disclosure provides methods and regimens for treating depression (e.g., treatment-resistant depression) in a patient (e.g., a patient in need of such treatment).  
WO/2016/025904A1
The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline f...  
WO/2016/023108A1
Drug delivery formulations useful to prevent or reduce purposeful or accidental overdose of a drug, and methods of making the same are provided. The formulations comprise either an alkalinizing coat in an amount sufficient to raise the p...  
WO/2016/025424A1
The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceut...  
WO/2016/023830A1
This invention relates to novel Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I) and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treat...  
WO/2016/025897A8
An analgesic composition is provided which is safe and effective to patients requiring pain modulation. The analgesic composition contains (a) acetaminophen and (b) at least three components chosen from (i) a bioavailable oral opioid; (i...  
WO/2016/025778A1
The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) adm...  
WO/2016/023832A1
This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula (I), and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents fo...  
WO/2016/023831A1
This invention relates to novel Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives of Formula (I), and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the tre...  
WO/2016/025918A1
The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.  
WO/2016/025790A1
Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biohynthetic pathway and methods of treating a disease using the inhibitors.  
WO/2016/025897A1
An analgesic composition is provided which is safe and effective to patients requiring pain modulation. The analgesic composition contains (a) acetaminophen and (b) at least three components chosen from (i) a bioavailable oral opioid; (i...  
WO/2016/024185A1
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.  
WO/2016/023401A1
Provided is a phosphorus-containing pyrido [2, 3-d] pyrimide-7-ketone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed are a preparation method of the compound, a pharmaceutical composi...  
WO/2016/024010A1
The present invention relates to a novel method for the treatment and/or prophylaxis of a tau-mediated neurodegenerative disease and/or of a tau-mediated neurodegenerative pathological condition, especially of a neurodegenerative disease...  
WO/2016/025789A8
Provided herein are compositions for inhibiting inflammation in a subject with a spinal cord injury comprising one or more agents capable of specifically reducing TNF-α signaling and a biodegradable carrier. Further provided herein are ...  
WO/2016/025669A1
The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic...  
WO/2016/024233A1
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...  
WO/2016/023825A1
This invention relates to novel Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the trea...  
WO/2016/023826A1
This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRP...  
WO/2016/025917A1
Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions ...  
WO/2016/025745A1
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form o...  
WO/2016/025789A1
Provided herein are compositions for inhibiting inflammation in a subject with a spinal cord injury comprising one or more agents capable of specifically reducing TNF-α signaling and a biodegradable carrier. Further provided herein are ...  
WO/2016/020944A1
The present invention has for object the use of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent...  
WO/2016/021711A1
 The present invention addresses the problem of providing a method for inexpensively, stably and industrially producing, at high yields, lacosamide having high optical purity. The abovementioned problem is solved by providing a method ...  
WO/2016/022947A1
The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers sel...  
WO/2016/020850A1
There is described a novel therapeutic use of antipsychotics and dopamine D2 receptor antagonists in the modulation of cognitive dysfunctions in a subject bearing a functional genetic variation in the DTNBP1 gene capable of reducing the ...  
WO/2016/021629A1
The present invention relates to: a compound represented by formula (I) (wherein -L- represents -C(=X)- or the like, -Z- represents -NR5- or the like, -ZA- represents -NR5A- or the like, -W- represents -C(R8R9)n-, -WA- represents -C(R3R4...  
WO/2016/022827A1
Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.  
WO/2016/020732A1
The current application relates to a pharmaceutical composition for the treatment or amelioration of a neurological disease, wherein the composition comprises a therapeutically effective amount of a caspase-6 inhibitor which is an arylpr...  
WO/2016/021508A1
The present invention provides an epitope peptide derived from CDCA1 and having a cytotoxic T-cell induction ability. The present invention also provides: a polynucleotide for coding the peptide; an antigen-presenting cell presenting the...  
WO/2016/022839A1
Disclosed herein, inter alia, are compositions and methods for modulating the unfolded protein response.  
WO/2016/022538A1
Provided herein are methods for identifying and treating subjects having conditions involving reduced HSF1 activity (e.g., diminished HSF1 activity, diminished HSF1 protein levels, increased HSF1 Ser303 phosphorylation, increased HSF1 Se...  
WO/2016/020488A1
Myo-inositol and one or more probioticfor use to improve insulin sensitivity and/or treat or prevent type II diabetes and/or to prevent CVD and/or a condition associated with a low insulin sensitivity and/or any of the foregoing in a sub...  
WO/2016/020853A1
The invention describes the preparation of new cocoa bean and grape seed extracts and their use, and use of their mixtures in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depress...  
WO/2016/021835A1
The present invention relates to a preparation method of drug-containing sustained release microparticles, the preparation method comprising the steps of: (a) dissolving a biodegradable polymer and a drug in a halogenated alkane solvent ...  
WO/2016/020307A1
Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a...  
WO/2016/019881A1
Disclosed is a method for preparing biocompatible, biodegradable microparticles having a controllable release profile for release of a biologically active agent contained in the microparticles. By adjusting the time period of treating th...  
WO/2016/020855A1
The invention describes the preparation of new grape seed extracts and their use in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of p...  
WO/2016/020786A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositio...  

Matches 651 - 700 out of 112,611